Jung-Mao Hsu

Dikutip oleh

	Semua	Sejak 2020
Kutipan	12768	8527
indeks-h	44	35
indeks-i10	54	52

2000

1000

500

1500

20082009201020112012201320142015201620172018201920202021202220232024202584 116 151 219 294 387 400 371 374 403 555 759 1067 1454 1783 1837 1984 400

Akses publik

Lihat semua

44 artikel

1 artikel

tersedia

tidak tersedia

Berdasarkan pada mandat pendanaan

Pengarang bersama

Mien-Chie HungChina Medical University, TaiwanEmail yang diverifikasi di cmu.edu.tw
Hirohito YamaguchiGraduate Institute of Biomedical Sciences, China Medical University, TaiwanEmail yang diverifikasi di mail.cmu.edu.tw
Li-Chuan ChanBoehringer Ingelheim Pharmaceuticals, Inc.Email yang diverifikasi di boehringer-ingelheim.com
Chun-Te ChenOBI pharmaEmail yang diverifikasi di obipharma.com
Chao-Kai ChouUT MD Anderson Cancer CenterEmail yang diverifikasi di mdanderson.org
Heng-Huan LeePostdoctoral Fellow of Biomedical Science, MD Anderson Cancer CenterEmail yang diverifikasi di mdanderson.org
Dung-Fang LeeUTHealth McGovern Medical SchoolEmail yang diverifikasi di uth.tmc.edu
Dihua YuandersonEmail yang diverifikasi di mdanderson.org
Seung Oe LimAssociate Professor, College of Pharmacy, Purdue UniversityEmail yang diverifikasi di purdue.edu
Jong-Ho chaDepartment of Biomedical Sciences, College of Medicine, Inha University, Incheon 22212, KoreaEmail yang diverifikasi di inha.ac.kr
Yun-Ju LaiAssistant Professor of Nursing, University of Massachusetts LowellEmail yang diverifikasi di uml.edu
Jer-Yen YangAssociate Professor of Cancer and Developmental Biology, China Medical University, TaiwanEmail yang diverifikasi di cmu.edu.tw
Hsin-Wei LiaoMD Anderson Cancer CenterEmail yang diverifikasi di mdanderson.org
Riyao YangAssistant ProfessorEmail yang diverifikasi di mdanderson.org
Kay-Hooi KhooAcademia Sinica, TaiwanEmail yang diverifikasi di gate.sinica.edu.tw
Hui-Lung SunUniversity of chicagoEmail yang diverifikasi di uchicago.edu
Yi-Hsin HsuThe Office of Human Subjects Protection (OHSP), The University of Texas M. D. Anderson CancerEmail yang diverifikasi di mdanderson.org
Mei-Kuang ChenMD Anderson Cancer CenterEmail yang diverifikasi di mdanderson.org
Taewan KimAssociate Professor (Pengcheng Distinguished), Shenzhen UniversityEmail yang diverifikasi di buckeyemail.osu.edu
Chung Hsuan ChenAcademia Sinica; Oak Ridge National Laboratory; University of ChicagoEmail yang diverifikasi di gate.sinica.edu.tw

Ikuti

Jung-Mao Hsu

China Medical University, Taiwan

Email yang diverifikasi di mail.cmu.edu.tw

Cancer Biology Immunotherapy


Judul Urutkan menurut kutipan Urutkan menurut tahun Urutkan menurut judul	Dikutip oleh Dikutip oleh	Tahun
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity CW Li, SO Lim, W Xia, HH Lee, LC Chan, CW Kuo, KH Khoo, SS Chang, ... Nature communications 7 (1), 12632, 2016	1024	2016
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression S Jiao, W Xia, H Yamaguchi, Y Wei, MK Chen, JM Hsu, JL Hsu, WH Yu, ... Clinical Cancer Research 23 (14), 3711-3720, 2017	938	2017
IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway DF Lee, HP Kuo, CT Chen, JM Hsu, CK Chou, Y Wei, HL Sun, LY Li, ... Cell 130 (3), 440-455, 2007	835	2007
PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis J Hou, R Zhao, W Xia, CW Chang, Y You, JM Hsu, L Nie, Y Chen, ... Nature cell biology 22 (10), 1264-1275, 2020	737	2020
Deubiquitination and stabilization of PD-L1 by CSN5 SO Lim, CW Li, W Xia, JH Cha, LC Chan, Y Wu, SS Chang, WC Lin, ... Cancer cell 30 (6), 925-939, 2016	714	2016
Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1 CW Li, SO Lim, EM Chung, YS Kim, AH Park, J Yao, JH Cha, W Xia, ... Cancer cell 33 (2), 187-201. e10, 2018	539	2018
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling CJ Chang, JY Yang, W Xia, CT Chen, X Xie, CH Chao, WA Woodward, ... Cancer cell 19 (1), 86-100, 2011	487	2011
Degradation of Mcl-1 by β-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization Q Ding, X He, JM Hsu, W Xia, CT Chen, LY Li, DF Lee, JC Liu, Q Zhong, ... Molecular and cellular biology 27 (11), 4006-4017, 2007	483	2007
Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth Y Yang, CW Li, LC Chan, Y Wei, JM Hsu, W Xia, JH Cha, J Hou, JL Hsu, ... Cell research 28 (8), 862-864, 2018	451	2018
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy R Yang, L Sun, CF Li, YH Wang, J Yao, H Li, M Yan, WC Chang, JM Hsu, ... Nature communications 12 (1), 832, 2021	445	2021
The crosstalk of mTOR/S6K1 and Hedgehog pathways Y Wang, Q Ding, CJ Yen, W Xia, JG Izzo, JY Lang, CW Li, JL Hsu, ... Cancer cell 21 (3), 374-387, 2012	414	2012
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion JM Hsu, W Xia, YH Hsu, LC Chan, WH Yu, JH Cha, CT Chen, HW Liao, ... Nature communications 9 (1), 1908, 2018	393	2018
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics H Yamaguchi, JM Hsu, WH Yang, MC Hung Nature Reviews Clinical Oncology 19 (5), 287-305, 2022	347	2022
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion LC Chan, CW Li, W Xia, JM Hsu, HH Lee, JH Cha, HL Wang, WH Yang, ... The Journal of clinical investigation 129 (8), 3324-3338, 2019	301	2019
Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer L Nie, HJ Wu, JM Hsu, SS Chang, AM LaBaff, CW Li, Y Wang, JL Hsu, ... American journal of translational research 4 (2), 127, 2012	276	2012
Nuclear trafficking of the epidermal growth factor receptor family membrane proteins YN Wang, H Yamaguchi, JM Hsu, MC Hung Oncogene 29 (28), 3997-4006, 2010	272	2010
Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation JM Hsu, CT Chen, CK Chou, HP Kuo, LY Li, CY Lin, HJ Lee, YN Wang, ... Nature cell biology 13 (2), 174-181, 2011	265	2011
Posttranslational modifications of PD-L1 and their applications in cancer therapy JM Hsu, CW Li, YJ Lai, MC Hung Cancer research 78 (22), 6349-6353, 2018	257	2018
Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3β activity and associates with poor prognosis in human breast cancer Q Ding, X He, W Xia, JM Hsu, CT Chen, LY Li, DF Lee, JY Yang, X Xie, ... Cancer research 67 (10), 4564-4571, 2007	248	2007
TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis Z Jiang, SO Lim, M Yan, JL Hsu, J Yao, Y Wei, SS Chang, H Yamaguchi, ... The Journal of clinical investigation 131 (8), 2021	247	2021

Sistem tidak dapat melakukan operasi ini. Coba lagi nanti.

Artikel 1–20

Kutipan per tahun

Kutipan duplikat

Kutipan yang digabung

Tambahkan pengarang bersamaPengarang bersama

Ikuti

Dikutip oleh

Pengarang bersama